Download PDF
Psychiatr Prax 2021; 48(S 01): S31-S36
DOI: 10.1055/a-1369-3133
Originalarbeit

Der Einsatz von Künstlicher Intelligenz bei Alzheimer-Krankheit – Personalisierte Diagnostik und Therapie

The Use of Artificial Intelligence in Alzheimerʼs Disease – Personalized Diagnostics and Therapy
Jens Wiltfang
1   Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Göttingen
2   Deutsches Zentrum für Neurodegenerative Erkrankungen, Standort Göttingen (DZNE-Göttingen)
,
Hermann Esselmann
1   Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Göttingen
,
Utako B. Barnikol
3   Angewandte Ethik in der translationalen Krebsforschung, Clearingstelle Ethik, Centrum für Integrierte Onkologie (CIO), Uniklinik Köln
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Am Beispiel der Demenz bei Alzheimer-Krankheit wird aufgezeigt, welche Chancen, aber auch Risiken neuere methodische Ansätze der Künstlichen Intelligenz (KI) (Artificial Intelligence, AI) für die Diagnostik und Therapie der Alzheimer-Demenz (AD) bieten. Daneben wird KI im Kontext einer ethisch-philosophischen Technologiekritik beleuchtet.

Abstract

Using the example of dementia in Alzheimer’s disease, it is shown which opportunities but also risks are posed by newer methodological approaches of artificial intelligence (AI) for the diagnosis and treatment of Alzheimer’s dementia (AD). In addition, AI is examined in the context of an ethical-philosophical critique of technology.

Schlüsselwörter

Alzheimer-Demenz - Präzisionsmedizin - personalisierte Medizin - Künstliche Intelligenz - angewandte Ethik

Keywords

Alzheimer’s dementia - precision medicine - personalized medicine - artificial intelligence - applied ethics


Publication History

Article published online:
02 March 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Livingston G, Sommerlad A, Orgeta V. et al. Dementia prevention, intervention, and care. Lancet 2017; 390: 2673-2734
    CrossrefPubMedGoogle Scholar
  • 2 Cullen B, O’Neill B, Evans JJ. et al. A review of screening tests for cognitive impairment. J Neurol Neurosurg Psychiatr 2007; 78: 790-799
    CrossrefPubMedGoogle Scholar
  • 3 Jessen F, Amariglio RE, Buckley RF. et al. The characterisation of subjective cognitive decline. Lancet Neurol 2020; 19: 271-278
    CrossrefPubMedGoogle Scholar
  • 4 Klünemann HH, Kastner I, Kaczmarek V. DemTect – einfach, schnell und trotzdem zuverlässig, Frühdiagnostik bei Demenz. NeuroTransmitter 2011; 9: 44-46
    CrossrefPubMedGoogle Scholar
  • 5 Wiltfang J, Lewczuk P, Otto M. Biomarker bei Demenzen und anderen neurodegenerativen Erkrankungen. Nervenarzt 2016; 87: 1305-1309
    CrossrefPubMedGoogle Scholar
  • 6 Shahpasand-Kroner H, Klafki HW, Bauer C. et al. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease. Alzheimers Res Ther 2018; 10: 121 DOI: 10.1186/s13195-018-0448-x.
    CrossrefPubMedGoogle Scholar
  • 7 Vicario-Orri E, Opazo CM, Muñoz FJ. The pathophysiology of axonal transport in Alzheimer’s disease. J Alzheimers Dis 2015; 430: 1097-1113
    PubMedGoogle Scholar
  • 8 van Dyck CH. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise. Biol Psychiatry 2018; 83: 311-319
    CrossrefPubMedGoogle Scholar
  • 9 Ballard C, Aarsland D, Cummings J. et al. Drug repositioning and repurposing for Alzheimer disease. Nat Rev Neurol 2020; 12: 661-673
    CrossrefPubMedGoogle Scholar
  • 10 Mishra R, Li B. The Application of Artificial Intelligence in the Genetic Study of Alzheimer’s Disease. Aging Dis 2020; 11: 1567-1584
    CrossrefPubMedGoogle Scholar
  • 11 Noorbakhsh-Sabet N, Zand R, Zhang Y. et al. Artificial Intelligence Transforms the Future of Health Care. Am J Med 2019; 132: 795-801
    CrossrefPubMedGoogle Scholar
  • 12 Miller RA. Medical diagnostic decision support systems – past, present, and future: a threaded bibliography and brief commentary. J Am Med Inform Assoc 1994; 1: 8-27
    CrossrefPubMedGoogle Scholar
  • 13 Paranjpe MD, Taubes A, Sirota M. Insights into Computational Drug Repurposing for Neurodegenerative Disease. Trends Pharmacol Sci 2019; 40: 565-576
    CrossrefPubMedGoogle Scholar
  • 14 Neuner SM, Tcw J, Goate AM. Genetic architecture of Alzheimer’s disease. Neurobiol Dis 2020; 143: 104976 DOI: 10.1016/j.nbd.2020.104976.
    CrossrefPubMedGoogle Scholar
  • 15 Bartels C, Belz M, Vogelgsang J. et al. To Be Continued? Long-Term Treatment Effects of Antidepressant Drug Classes and Individual Antidepressants on the Risk of Developing Dementia: A German Case-Control Study. J Clin Psychiatry 2020; 81: 19m13205 DOI: 10.4088/JCP.19m13205.
    CrossrefPubMedGoogle Scholar
  • 16 Bartels C, Wagner M, Wolfsgruber S. et al. Alzheimer’s Disease Neuroimaging Initiative. Impact of SSRI Therapy on Risk of Conversion from Mild Cognitive Impairment to Alzheimer’s Dementia in Individuals With Previous Depression. Am J Psychiatry 2018; 175: 232-241
    CrossrefPubMedGoogle Scholar
  • 17 Reddy OC, van der Werf YD. The Sleeping Brain: Harnessing the Power of the Glymphatic System through Lifestyle Choices. Brain Sci 2020; 10: 868 DOI: 10.3390/brainsci10110868.
    CrossrefPubMedGoogle Scholar
  • 18 Ding Y, Sohn JH, Kawczynski MG. et al. A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using (18) F-FDG PET of the Brain. Radiology 2019; 290: 456-464
    CrossrefPubMedGoogle Scholar
  • 19 de la Fuente Garcia S, Ritchie CW, Luz S. Artificial Intelligence, Speech, and Language Processing Approaches to Monitoring Alzheimer’s Disease: A Systematic Review. J Alzheimers Dis 2020; 78: 1547-1574 DOI: 10.3233/JAD-200888.
    CrossrefPubMedGoogle Scholar
  • 20 Ashton NJ, Nevado-Holgado AJ, Barber IS. et al. A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease. Sci Adv 2019; 5: eaau7220 DOI: 10.1126/sciadv.aau7220.
    CrossrefPubMedGoogle Scholar
  • 21 Vogelgsang J, Wiltfang J, Klafki HW. Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma. Methods Mol Biol 2018; 1750: 111-124
    CrossrefPubMedGoogle Scholar
  • 22 Barthélemy NR, Li Y, Joseph-Mathurin N. et al. Dominantly Inherited Alzheimer Network. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat Med 2020; 26: 398-407
    CrossrefPubMedGoogle Scholar
  • 23 Mattsson-Carlgren N, Janelidze S, Palmqvist S. et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease. Brain 2020; 143: 3234-3241
    CrossrefPubMedGoogle Scholar
  • 24 Ovod V, Ramsey KN, Mawuenyega KG. et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 2017; 8: 841-849
    CrossrefPubMedGoogle Scholar
  • 25 Nakamura A, Kaneko N, Villemagne VL. et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature 2018; 554: 249-254
    CrossrefPubMedGoogle Scholar
  • 26 Pearson K. On lines and planes of closest fit to a system of points in space. The London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science 1901; 2: 559-572 DOI: 10.1080/14786440109462720.
    CrossrefPubMedGoogle Scholar
  • 27 Tanevski J, Nguyen Th, Truong B. et al. Predicting cells position from single-cell transcriptomics. Life Sci Alliance 2020; 3: e202000867 DOI: 10.26508/lsa.202000867.
    CrossrefPubMedGoogle Scholar
  • 28 Rajewsky N, Almouzni G, Gorski SA. et al. LifeTime and improving European healthcare through cell-based interceptive medicine. Nature 2020; 587: 377-386
    CrossrefPubMedGoogle Scholar
  • 29 Priebe S. Wo ist der Fortschritt?. Psychiat Prax 2012; 39: 55-56
    Article in Thieme ConnectPubMedGoogle Scholar